7-chloro-3,4-dihydronaphthalen-1(2H)-one oxime | 42071-42-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 7-chloro-3,4-dihydronaphthalen-1(2H)-one oxime
• 英文别名: 7-chloro-1-naphthalenone oxime；7-chloro-1-tetralone oxime；N-(7-chloro-3,4-dihydro-2H-naphthalen-1-ylidene)hydroxylamine
• CAS: 42071-42-1
• 化学式: C₁₀H₁₀ClNO
• 分子量: 195.648
• InChiKey: KNWZLQDFUWEVLX-UHFFFAOYSA-N

物化性质

• 沸点：
  349.9±41.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-chloro-3,4-dihydronaphthalen-1(2H)-one oxime 在 PPA 、 草酰氯 、 sodium hydride 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 88.5h， 生成 Ethanesulfonic acid (3-chloro-5-oxo-5,6,7,8-tetrahydro-naphthalen-1-yl)-amide
  参考文献：
  名称：

  Synthesis and Structure−Activity Studies on N-[5-(1H-Imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidazole-Containing α_1A-Adrenoceptor Agonist

  摘要：

  Structure-activity studies were performed on the alpha(1A)-adrenoceptor (AR) selective agonist N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide (4). Compounds were evaluated for binding activity at the alpha(1A), alpha(1b), alpha(1d), alpha(2a), and alpha(2B) subtypes. Functional activity in tissues containing the alpha(1A) (rabbit urethra), alpha(1B) (rat spleen), alpha(1D) (rat aorta), and alpha(2A) (rat prostatic vas deferens) was also evaluated. A dog in vivo model simultaneously measuring intraurethral pressure (IUP) and mean arterial pressure (ALAP) was used to assess the uroselectivity of the compounds. Many of the compounds that were highly selective in vitro for the alpha(1A)-AR subtype were also more uroselective in vivo for increasing IUP over MAP than the nonselective alpha(1)-agonists phenylpropanolamine (PPA) (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater alpha(1A) selectivity would reduce cardiovascular side effects. However, the data also support a prominent role of the alpha(1A)-AR subtype in the control of MAP.

  DOI：

  10.1021/jm030551a
• 作为产物：
  描述：

  3-(4-氯苯甲酰)丙酸 在 盐酸羟胺 、 sodium acetate 、 一水合肼 、 potassium hydroxide 作用下， 以 乙醇 、 乙二醇 为溶剂， 反应 6.33h， 生成 7-chloro-3,4-dihydronaphthalen-1(2H)-one oxime
  参考文献：
  名称：

  Schmidt反应和Beckmann重排在双环内酰胺合成中的应用：一些机理上的考虑

  摘要：

  据报道，使用两个不同的条件进行适当酮的施密特反应，并使用两个不同的条件进行相应酮肟的贝克曼重排，合成了一些类型3和4的甲氧基取代的双环内酰胺。通过反应的高效液相色谱分析来确定反应的烷基与芳基的迁移比。讨论了所报告反应的机制，确定了所报告机制的某些局限性，并根据各种反应的结果提出了另一种机制。施密特反应和贝克曼重排反应的应用被用于合成一些3型和3型氯双环内酰胺。4。

  DOI：

  10.1071/ch09402

文献信息

• Highly enantioselective [3+2] coupling of cyclic enamides with quinone monoimines promoted by a chiral phosphoric acid
  作者：Minmin Zhang、Shuowen Yu、Fangzhi Hu、Yijun Liao、Lihua Liao、Xiaoying Xu、Weicheng Yuan、Xiaomei Zhang

  DOI：10.1039/c6cc01200k

  日期：——

  Enantioselective [3+2] coupling of cyclic enamides with quinone monoimines was realised using a chiral phosphoric acid as a catalyst. This transformation allowed for the synthesis of highly enantioenriched polycyclic 2,3-dihydrobenzofurans...

  使用手性磷酸作为催化剂，实现环酰胺与醌单亚胺的对映选择性[3 + 2]偶联。该转化允许合成高度对映体富集的多环2,3-二氢苯并呋喃。
• The Application of the Schmidt Reaction and Beckmann Rearrangement to the Synthesis of Bicyclic Lactams: Some Mechanistic Considerations
  作者：Ian T. Crosby、James K. Shin、Ben Capuano

  DOI：10.1071/ch09402

  日期：——

  The syntheses of some methoxy-substituted bicyclic lactams, of the types 3 and 4, are reported employing two different conditions for the Schmidt reaction of appropriate ketones and employing two different conditions for the Beckmann rearrangement of the corresponding ketoximes. The alkyl to aryl migration ratios of the reactions were determined by high-performance liquid chromatography analysis of

  据报道，使用两个不同的条件进行适当酮的施密特反应，并使用两个不同的条件进行相应酮肟的贝克曼重排，合成了一些类型3和4的甲氧基取代的双环内酰胺。通过反应的高效液相色谱分析来确定反应的烷基与芳基的迁移比。讨论了所报告反应的机制，确定了所报告机制的某些局限性，并根据各种反应的结果提出了另一种机制。施密特反应和贝克曼重排反应的应用被用于合成一些3型和3型氯双环内酰胺。4。
• 一种左旋胺基化合物的合成方法
  申请人：王际菊

  公开号：CN106467476A

  公开（公告）日：2017-03-01

  本发明公开了一种左旋胺基化合物S‑7‑氯‑1,2,3,4‑四氢萘‑1‑胺的合成方法,本发明的具体方法是以7‑氯‑1萘满酮为原料，与羟胺反应成肟，肟进行氢化还原得外消旋胺，将反应所得产物胺与脂肪酶，消旋催化剂，酰基供体一起进行一锅化的动态动力学拆分反应，拆分反应产物再进行水解，即可得S‑7‑氯‑1,2,3,4‑四氢萘‑1‑胺。本发明具备操作简单、产品收率好、拆分产品光学纯度高等特点。
• 1,3,8-triazaspiro[4,5]decan-4-one derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06071925A1

  公开（公告）日：2000-06-06

  The present invention relates to compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each independently hydrogen, lower alkyl, lower alkoxy or halogen; R.sup.3 is phenyl, which is unsubstituted or substituted by lower alkyl, CF.sub.3, lower alkoxy or halogen; R.sup.4 is hydrogen, lower alkyl, lower alkenyl, --C(O)-lower alkyl, --C(O)-phenyl, lower alkyl-C(O)-phenyl, lower alkylene-C(O)O-lower alkyl, lower alkantriyl-di-C(O)O-lower alkyl, hydroxy-lower alkyl, lower alkyl-O-lower alkyl, lower alkyl-CH(OH)CF.sub.3, phenyl or benzyl, R.sup.5 and R.sup.6 are each independently hydrogen, phenyl, lower alkyl or di-lower alkyl or R.sup.5 and R.sup.6 together with the carbon atoms to which they are bound form a phenyl ring, or R.sup.5 and one of R.sup.1 or R.sup.2 together with the carbon atoms to which they are bound form a saturated or unsaturated 6 membered ring, A is a 4-7 membered saturated ring, their racemates and the enantiomers thereof, and the pharmaceutically acceptable acid addition salts thereof which are agonists and/or antagonists of the OFQ receptor.

  本发明涉及以下式子的化合物：##STR1## 其中R.sup.1和R.sup.2各自独立地为氢、低烷基、低烷氧基或卤素; R.sup.3为苯，未取代或取代为低烷基、CF.sub.3、低烷氧基或卤素; R.sup.4为氢、低烷基、低烯基、--C（O）-低烷基、--C（O）-苯、低烷基-C（O）-苯、低烷基亚烷基-C（O）O-低烷基、低烷三基-二-C（O）O-低烷基、羟基-低烷基、低烷基-O-低烷基、低烷基-CH（OH）CF.sub.3、苯或苄基，R.sup.5和R.sup.6各自独立地为氢、苯、低烷基或二-低烷基，或R.sup.5和R.sup.6与它们所结合的碳原子形成苯环，或R.sup.5和R.sup.1或R.sup.2中的一个与它们所结合的碳原子形成饱和或不饱和的6元环，A为4-7元饱和环，它们的外消旋体和对映异构体，以及在药学上可接受的酸加盐，它们是OFQ受体的激动剂和/或拮抗剂。
• Synthesis and Structure−Activity Studies on <i>N</i>-[5-(1<i>H</i>-Imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an Imidazole-Containing α_1A-Adrenoceptor Agonist
  作者：Robert J. Altenbach、Albert Khilevich、Teodozyj Kolasa、Jeffrey J. Rohde、Pramila A. Bhatia、Meena V. Patel、Xenia B. Searle、Fan Yang、William H. Bunnelle、Karin Tietje、Erol K. Bayburt、William A. Carroll、Michael D. Meyer、Rodger Henry、Steven A. Buckner、Jane Kuk、Anthony V. Daza、Ivan V. Milicic、John C. Cain、Chae H. Kang、Lynne M. Ireland、Tracy L. Carr、Thomas R. Miller、Arthur A. Hancock、Masaki Nakane、Timothy A. Esbenshade、Michael E. Brune、Alyssa B. O'Neill、Donna M. Gauvin、Sweta P. Katwala、Mark W. Holladay、Jorge D. Brioni、James P. Sullivan

  DOI：10.1021/jm030551a

  日期：2004.6.1

  Structure-activity studies were performed on the alpha(1A)-adrenoceptor (AR) selective agonist N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide (4). Compounds were evaluated for binding activity at the alpha(1A), alpha(1b), alpha(1d), alpha(2a), and alpha(2B) subtypes. Functional activity in tissues containing the alpha(1A) (rabbit urethra), alpha(1B) (rat spleen), alpha(1D) (rat aorta), and alpha(2A) (rat prostatic vas deferens) was also evaluated. A dog in vivo model simultaneously measuring intraurethral pressure (IUP) and mean arterial pressure (ALAP) was used to assess the uroselectivity of the compounds. Many of the compounds that were highly selective in vitro for the alpha(1A)-AR subtype were also more uroselective in vivo for increasing IUP over MAP than the nonselective alpha(1)-agonists phenylpropanolamine (PPA) (1) and ST-1059 (2, the active metabolite of midodrine), supporting the hypothesis that greater alpha(1A) selectivity would reduce cardiovascular side effects. However, the data also support a prominent role of the alpha(1A)-AR subtype in the control of MAP.